Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global vegetarian capsules market is anticipated to grow at a considerable CAGR during the forecast period through 2027, according to a report by Research & Markets.
read more
Sandoz, a manufacturer of generic and biosimilar medicines, announced the US launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech's Esbriet®*, to treat patients with idiopathic pulmonary fibrosis (IPF).1 This prescription oral medicine is immediately available to patients via specialty pharmacies, with...
read more
Astex Pharmaceuticals announce results from the ASCERTAIN phase 3 study evaluating oral decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) tablets versus IV decitabine in adults with AML who are not candidates to receive standard induction chemotherapy.
read more
Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily...
read more
The global diabetes therapeutics industry was estimated at $1.3B in 2020, and is anticipated to hit $3.4B by 2030, registering a CAGR of 10.4% from 2021 to 2030, according to the Allied Market Research report “Diabetes Therapeutics Market”.
read more
The orthostatic hypotension drugs market value is set to grow by $571.76M 2021 to 2026, progressing at a CAGR of 9.06% as per the latest market report by Technavio.
read more
Axsome Therapeutics, a biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders, announced the completion of its U.S. acquisition of Sunosi® (solriamfetol) from Jazz Pharmaceuticals.
read more
The global gelatin type hard capsules market is anticipated to grow at a considerable CAGR during the forecast period.
read more
Juniper Biologics, a healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, signed an exclusive license agreement to develop and commercialize ...
read more
Results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF). The trial was conducted in patients with HF with mildly reduced or preserved ejection fraction (...
read more
Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science solutions to ensure product protection, extend shelf life and improve patient experience, will preview its first-ever active bottle featuring post-consumer recycled (PCR) content at VitaFoods Europe, Booth J60, May 10-12 in Geneva, Switzerland.
read more
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has completed patient enrollment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D), surpassing its target of 675 patients with 710 ...
read more
Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior ...
read more
Bayer announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
read more
The global dietary supplements market is expected to reach $288.5 billion by 2030 from $123.1 billion in 2021, growing at a CAGR of 9.9% from 2021 to 2030.
read more